Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anlotinib + CAPEOX in RAS/BRAF Wild-type mCRC
NCT04080843Phase 2Completed
- Sponsor
- Zhejiang University
- Start
- Nov 2019
- Primary completion
- Jun 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of anlotinib in metastatic colorectal cancer (mCRC), sponsored by Zhejiang University. Started Nov 2019; status: completed.
02
Drugs
anlotinib
03
Conditions
metastatic colorectal cancer (mCRC)
Beyond the preview
Go deeper on NCT04080843.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04080843.